Li Chunhong, Liang Jing, Xiang Huiling, Chen Haiyan, Tian Jie
Depatrment of Nephrology, The Third Central Clinical College of Tianjin Medical University.
Department of Nephrology, The Third Central Hospital of Tianjin.
Medicine (Baltimore). 2020 Nov 25;99(48):e23384. doi: 10.1097/MD.0000000000023384.
Hepatitis C virus (HCV) infection is very common in maintenance hemodialysis patients, causing high morbidity and mortality. This study aimed to evaluate the effectiveness and adverse events of direct-acting antivirals (DAAs) in maintenance hemodialysis patients complicated with chronic hepatitis C in real-world clinical practice.In this retrospective observational study, hemodialysis patients with chronic hepatitis C infection in the Third Central Hospital of Tianjin outpatient were screened, and appropriate treatment plans were selected accordingly. Totally 25 patients diagnosed with chronic hepatitis C and treated with DAAs for 12 weeks or 24 weeks were included. The sustained virologic response (SVR) rate obtained 12 weeks post-treatment (SVR12) was evaluated. Laboratory indexes and adverse reactions during the treatment process were also assessed.A total of 25 cases met the eligibility criteria and provided informed consent. Except for 1 patient who discontinued the treatment due to gastrointestinal bleeding, the remaining 24 cases completed the treatment cycle with 100% rapid virologic response (RVR) and 100% SVR12, with no serious adverse reactions recorded.Maintenance hemodialysis patients complicated with chronic hepatitis C in Chinese real-world setting tolerate DAAs very well, with a viral response rate reaching 100%.
丙型肝炎病毒（HCV）感染在维持性血液透析患者中非常常见，会导致高发病率和死亡率。本研究旨在评估直接抗病毒药物（DAAs）在实际临床实践中对合并慢性丙型肝炎的维持性血液透析患者的有效性和不良事件。在这项回顾性观察研究中，对天津市第三中心医院门诊的慢性丙型肝炎感染血液透析患者进行筛查，并据此选择合适的治疗方案。共纳入25例诊断为慢性丙型肝炎并接受DAAs治疗12周或24周的患者。评估治疗后12周获得的持续病毒学应答（SVR）率。还评估了治疗过程中的实验室指标和不良反应。共有25例符合入选标准并签署知情同意书。除1例因胃肠道出血中断治疗外，其余24例均完成治疗周期，快速病毒学应答（RVR）率和SVR12均达100%，未记录到严重不良反应。在中国实际临床环境中，合并慢性丙型肝炎的维持性血液透析患者对DAAs耐受性良好，病毒应答率达100%。
